JP2023514788A5 - - Google Patents

Info

Publication number
JP2023514788A5
JP2023514788A5 JP2022551251A JP2022551251A JP2023514788A5 JP 2023514788 A5 JP2023514788 A5 JP 2023514788A5 JP 2022551251 A JP2022551251 A JP 2022551251A JP 2022551251 A JP2022551251 A JP 2022551251A JP 2023514788 A5 JP2023514788 A5 JP 2023514788A5
Authority
JP
Japan
Prior art keywords
cells
subject
nkt cells
nkt
hed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019773 external-priority patent/WO2021173900A1/en
Publication of JP2023514788A publication Critical patent/JP2023514788A/ja
Publication of JP2023514788A5 publication Critical patent/JP2023514788A5/ja
Pending legal-status Critical Current

Links

JP2022551251A 2020-02-28 2021-02-26 リンパ球集団およびそれを生産するための方法 Pending JP2023514788A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062983005P 2020-02-28 2020-02-28
US62/983,005 2020-02-28
US202063009050P 2020-04-13 2020-04-13
US63/009,050 2020-04-13
US202063123054P 2020-12-09 2020-12-09
US63/123,054 2020-12-09
PCT/US2021/019773 WO2021173900A1 (en) 2020-02-28 2021-02-26 Lypmphocyte population and methods for producing same

Publications (2)

Publication Number Publication Date
JP2023514788A JP2023514788A (ja) 2023-04-10
JP2023514788A5 true JP2023514788A5 (enExample) 2024-03-01

Family

ID=75108879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551251A Pending JP2023514788A (ja) 2020-02-28 2021-02-26 リンパ球集団およびそれを生産するための方法

Country Status (11)

Country Link
US (1) US20230096897A1 (enExample)
EP (1) EP4110902A1 (enExample)
JP (1) JP2023514788A (enExample)
KR (1) KR20220148859A (enExample)
CN (1) CN115516085A (enExample)
AU (1) AU2021227925A1 (enExample)
BR (1) BR112022016803A2 (enExample)
CA (1) CA3168378A1 (enExample)
IL (1) IL295952A (enExample)
MX (1) MX2022010674A (enExample)
WO (1) WO2021173900A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230172950A1 (en) * 2020-04-29 2023-06-08 Avm Biotechnology, Llc Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus
EP4395784A1 (en) * 2021-09-01 2024-07-10 AVM Biotechnology, LLC Lymphocyte population and methods for producing same
CN114561362B (zh) * 2021-12-28 2023-12-15 江西省疾病预防控制中心 一种人源肾综合征出血热汉坦病毒分离方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
WO2012074116A1 (ja) * 2010-12-02 2012-06-07 独立行政法人理化学研究所 アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体(TCR)遺伝子のα鎖領域が均一なVα-Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
EP3490605B1 (en) * 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
CA3106056A1 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesu (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN113286811B (zh) * 2018-07-30 2024-12-06 南加利福尼亚大学 改善过继性细胞疗法的效力和安全性
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Similar Documents

Publication Publication Date Title
Peng et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy
Qi et al. Gamma delta T cells and their pathogenic role in psoriasis
JP2020518289A5 (enExample)
CA2446981C (fr) Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2023514788A5 (enExample)
Valentine et al. CXCR5+ CD8 T cells: protective or pathogenic?
JP2022002517A (ja) 非造血組織常在性γδ T細胞の増幅および該細胞の使用
CN104245923B (zh) 同种异型抗原‑反应性调节t细胞的增殖
CN107002039B (zh) 使用t细胞用于培养自然杀伤细胞的方法
US20220380727A1 (en) Generation of engineered regulatory t cells
Biernacki et al. T cell optimization for graft-versus-leukemia responses
JP5937003B2 (ja) 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性t細胞のエクスビボ増加方法
US20190351019A1 (en) Steroid administration and immunotherapy
JP2016539929A5 (enExample)
JP2000509604A (ja) サプレッサー細胞集団を生成するためのインターロイキン―10の使用
JP2024513522A5 (enExample)
Sakai et al. Regulatory T cells: pathophysiological roles and clinical applications
TW202325320A (zh) 用於產生原代免疫細胞之方法
US20220175834A1 (en) Methods for culturing immune cells
Peng et al. A cultured malignant B-1 line serves as a model for Richter's syndrome.
JP2023524434A5 (enExample)
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
Gao et al. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease
Pothoven et al. Rapamycin-conditioned donor dendritic cells differentiate CD4+ CD25+ Foxp3+ T cells in vitro with TGF-β1 for islet transplantation
JP2024533093A5 (enExample)